Heidelberg, Germany, February 21, 2019 -- Affimed N.V. (Nasdaq: AFMD), a
clinical stage biopharmaceutical company committed to improving patient
outcomes through the power of the innate immune system, today announced
that Dr. Adi Hoess, Chief Executive Officer, will present at the
following upcoming investor conferences:
-- 8th Annual SVB Leerink Global Healthcare Conference on Thursday, February
28, 2019 at 1:00 p.m. Eastern Time in New York
-- Cowen and Company 39th Annual Health Care Conference on Wednesday, March
13, 2019 at 8:40 a.m. Eastern Time in Boston
A live webcast of each presentation will be available from the investor
relations section of Affimed's website at
https://www.affimed.com/investors/webcasts/ and will be archived for 30
days following the event.
About Affimed N.V.
Affimed (Nasdaq: AFMD) is a clinical stage biopharmaceutical company
that engineers targeted immunotherapies, seeking to improve patient
outcomes through the power of innate immunity. Affimed's fit-for-purpose
ROCK(R) platform allows innate immune engagers to be designed for
specific patient populations. The Company is developing single and
combination therapies to treat cancers. For more information, please
visit www.affimed.com.
Affimed Investor Contact:
Gregory Gin, Head of Investor Relations
E-Mail: IR@affimed.com
Affimed Media Contact:
Anca Alexandru, Head of Communications, EU IR
E-Mail: media@affimed.com
(END) Dow Jones Newswires
February 21, 2019 07:30 ET (12:30 GMT)
© 2019 Dow Jones News
